LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, today announced Q4 2010 financial
results. The Company posted record quarterly sales of $14.4mm and
adjusted operating income of $938,000. During Q4 2010 the company
acquired the LifeSpan ePTFE graft business and agreed to buy out
its distributors in Spain and Denmark. The Company also declared a
quarterly cash dividend of $0.02 per share of its common stock.
Q4 2010 sales increased 6% (+9% organic) versus Q4 2009, driven
by 14% growth in the Americas. Full-year 2010 sales increased 10%
(+12% organic) versus 2009, driven by a 17% increase in sales of
products in the Vascular category and an 18% increase in the
Americas. Vascular accounted for 71% of revenues in 2010 while the
Americas accounted for 62%.
The Company reported a gross margin of 71.7% in Q4 2010, versus
74.9% in Q4 2009. The decrease was largely due to costs
related to the closure and relocation of the Company's Italian
graft manufacturing facility. Full year 2010 gross margin increased
to 74.4% from 73.3% in 2009, due to increased manufacturing
efficiencies and higher average selling prices.
Excluding restructuring and impairment charges, Q4 2010
operating income was $938,000. Reported Q4 2010 operating loss was
$1.0mm versus an operating profit of $1.2mm in Q4 2009. The
loss was driven by $1.6mm in restructuring charges from the closure
of the Italian factory, $0.4mm of TAArget/UniFit impairment
charges, and increased operating expenses. Full-year 2010
operating profit was a record $4.3mm versus $1.9mm in
2009. Sales growth and an expanded gross margin drove the
improvement.
Net income in Q4 2010 was $2.1mm, or $0.13 per diluted share,
versus $1.3mm in Q4 2009, or $0.08 per diluted share. Q4 2010
net income benefited from a $2.3mm one-time, non-cash, credit to
the tax provision. Net income for 2010 was $6.2mm, or $0.38
per diluted share, versus $1.6mm, or $0.10 per diluted share, in
2009.
George W. LeMaitre, Chairman and CEO, said, "In 2010 sales grew
12% organically, and operating income doubled to $4.3mm. Due
to the company's increasing earnings power, we have initiated
quarterly dividends. I view this as a complement to our share
repurchase program as we work to maximize shareholder value.
Additionally, in Q4 2010 we acquired the LifeSpan ePTFE
business and agreed to buy out our Spanish and Danish distributors.
These moves broaden our vascular offering and strengthen our
direct-to-hospital sales channel."
The Company's cash and marketable securities decreased by $5.1mm
during Q4 2010 to $22.6mm at December 31, 2010. The decrease was
largely due to $3.5mm related to the purchase of LifeSpan, $1.6mm
in employee termination costs in Italy, and $1.2mm of share
repurchases.
Sales and marketing expenses increased 5% in Q4 2010 to
$5.1mm. The Company ended 2010 with 67 sales representatives
versus 61 at the end of 2009.
General and administrative expenses increased 18% in Q4 2010 to
$2.9mm. Increases were due to additional management personnel
and compensation, as well as acquisition-related expenses.
R&D expenses decreased 14% to $1.5mm in Q4 2010, a result of
decreased regulatory and clinical affairs spending as the Company
suspended its TAArget/UniFit clinical trials.
Business Development
On November 17, 2010 the Company acquired the LifeSpan Vascular
Graft manufacturing business from Angiotech Pharmaceuticals for
$2.8mm. The Company also paid $1.2mm to Edwards LifeSciences,
the former LifeSpan distributor, in exchange for trademarks,
inventory, and an orderly market transition in Europe and Japan.
The Company expects LifeSpan sales of approximately $1.7mm in
2011. The transaction is expected to reduce operating
income by approximately $0.7mm in 2011 and be accretive
thereafter.
The Company also announced it will begin direct sales in Spain
and Denmark in July 2011. LeMaitre Vascular currently sells
its products in Spain and Denmark through independent distributors,
who have agreed to terminate their distribution rights and provide
detailed customer information and transition services for $1.3
million. In 2010 the Company sold $0.7mm of products to these
two distributors.
Dividend Initiation
The Company announced that its Board of Directors has approved a
policy for the payment of regular quarterly cash dividends on the
Company's common stock of $0.02 per share, payable on April 5,
2011, to shareholders of record at the close of business on March
22, 2011. Future declarations of quarterly dividends and the
establishment of future record and payment dates are subject to the
final determination of the Company's Board of Directors.
Business Outlook
The Company expects Q1 2011 sales of $14.5mm, and operating
income of $150,000. Q1 2011 operating income guidance
includes an estimated $1.2mm in largely non-cash charges related to
the closure of the Italian manufacturing facility, and the
distributor buyouts in Spain and Denmark.
The Company also revised its full-year 2011 sales guidance to
$62.0mm (+11% versus 2010), and maintained its 2011 operating
income guidance of $6.0mm (+40% versus 2010). This guidance
implies a 10% reported operating margin for
2011.
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. EST today
to review the Company's financial results and discuss its business
outlook for the remainder of the year. The conference call
will be broadcast live over the Internet. Individuals who are
interested in listening to the webcast should log on to the
Company's website at www.lemaitre.com/investor. The conference call
may also be accessed by dialing 866-202-3109 (+1-617-213-8844 for
international callers), using passcode 38744818. For individuals
unable to join the live conference call, a replay will be available
on the Company's website.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of
peripheral vascular disease, a condition that affects more than 20
million people worldwide. The Company develops, manufactures
and markets disposable and implantable vascular devices to address
the needs of its core customer, the vascular surgeon.
Well-known to vascular surgeons, the Company's diversified
product portfolio consists of brand name devices used in arteries
and veins outside of the heart, including the Expandable LeMaitre
Valvulotome, Pruitt F3 Carotid Shunt, and AlboGraft Vascular
Graft.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc. This press release
contains other trademarks and trade names of the Company.
For more information about the Company, please visit
http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to properly
understand the Company's short-term and long-term financial trends,
investors may wish to consider the impact of certain non-cash or
non-recurring or infrequently-occurring items, when used as a
supplement to financial performance measures in accordance with
GAAP. These items result from facts and circumstances that
vary in frequency and/or impact on continuing operations. In
addition, management uses results of operations before such items
to evaluate the operational performance of the Company and as a
basis for strategic planning. Investors should consider these
non-GAAP measures in addition to, and not as a substitute for,
financial performance measures in accordance with GAAP. In
addition to the description provided below, reconciliation of GAAP
to non-GAAP results is provided in the financial statement tables
included in this press release.
In this press release, the Company has reported a non-GAAP
financial measure, adjusted operating income, which excludes
certain expenses related to the closure of its Italian
manufacturing facility and its decision to reduce investment in its
stent graft program. During Q4 2010, the Company paid $1.6mm
in severance and related termination payments to the employees at
its Italian manufacturing facility, of which $1.6mm million was
charged to restructuring in Q4. The Company did not incur any
restructuring charges in Q4 2009. Also, during Q4 2010, the
Company decided to discontinue research and development activities
related to its stent graft program, which resulted in impairment
charges of $0.4 million. The Company did not incur any
impairment charges in Q4 2009.
In addition, this press release includes sales growth after
adjusting for foreign exchange, business development transactions,
and other events. The Company refers to this as "organic" sales
growth. The Company analyzes net sales on a constant currency
basis net of acquisitions and other non-recurring events to better
measure the comparability of results between periods. Because
changes in foreign currency exchange rates have a non-operating
impact on net sales, and acquisitions, product discontinuations,
and other strategic transactions are episodic in nature and highly
variable in sales impact, the Company believes that evaluating
growth in sales on a constant currency basis net of such
transactions provides an additional and meaningful assessment of
sales to both management and the Company's investors. During Q2
2010, the Company divested the OptiLock Implantable Port and
discontinued sales of the aSpire Stent, and in Q4 2010, the Company
acquired its LifeSpan Vascular Graft business.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding the Company's
business that are not historical facts may be "forward-looking
statements" that involve risks and
uncertainties. Specifically, statements regarding the
Company's financial and operational guidance, and its plans to
begin direct sales in Spain and Denmark, are forward-looking,
involving risks and uncertainties. The Company's current
quarterly financial results, as discussed in this release, are
preliminary and unaudited, and subject to
adjustment. Forward-looking statements are based on
management's current, preliminary expectations and are subject to
risks and uncertainties that could cause actual results to differ
from the results predicted. These risks and uncertainties
include, but are not limited to, the risk that the Company may not
realize the anticipated benefits of its acquisitions; the risk that
the Company is not successful in transitioning to a direct selling
model in Spain and Denmark; the risk that the Company experiences
production delays or quality difficulties in the consolidation of
its manufacturing operations; the risk that the Company does not
generate sufficient operating scale to maintain or increase
profitability; risks related to product demand and market
acceptance of the Company's products; the possibility that the
Company's new products may fail to provide the desired safety and
efficacy or may not be accepted by the market for other reasons;
the significant competition the Company faces from other companies,
technologies, and alternative medical procedures; the risk that the
Company may fail to expand its product offerings through internal
development or acquisition; the general uncertainty related to
seeking regulatory approvals for the Company's products; and other
risks and uncertainties included under the heading "Risk Factors"
in our most recent Annual Report on Form 10-K, as updated by our
subsequent filings with the SEC, all of which are available on the
Company's investor relations website at http://www.lemaitre.com and
on the SEC's website at http://www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. The Company undertakes no obligation
to update publicly any forward-looking statements to reflect new
information, events, or circumstances after the date they were
made, or to reflect the occurrence of unanticipated events.
Financial Statements
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
CONDENSED CONSOLIDATED BALANCE
SHEETS |
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
December 31,
2010 |
December 31,
2009 |
|
(unaudited) |
|
Assets |
|
|
|
|
|
Current assets: |
|
|
Cash and cash equivalents |
$ 22,614 |
$ 23,192 |
Marketable securities |
-- |
808 |
Accounts receivable, net |
8,475 |
7,778 |
Inventories |
8,375 |
6,498 |
Other current assets |
3,357 |
1,274 |
|
|
|
Total current assets |
42,821 |
39,550 |
|
|
|
Property and equipment, net |
3,806 |
2,101 |
Goodwill |
11,917 |
11,022 |
Other intangibles, net |
3,686 |
3,316 |
Other assets |
954 |
917 |
|
|
|
Total assets |
$ 63,184 |
$ 56,906 |
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
Current liabilities: |
|
|
Accounts payable |
$ 1,320 |
$ 1,136 |
Accrued expenses |
8,223 |
5,412 |
Acquisition-related
liabilities |
441 |
-- |
Total current liabilities |
9,984 |
6,548 |
|
|
|
Long term debt |
155 |
188 |
Deferred tax liabilities |
443 |
1,546 |
Other long-term liabilities |
86 |
411 |
Total liabilities |
10,668 |
8,693 |
|
|
|
Stockholders' equity |
|
|
Common stock |
161 |
159 |
Additional paid-in capital |
64,642 |
63,475 |
Accumulated deficit |
(8,423) |
(14,596) |
Accumulated other comprehensive
gain (loss) |
(429) |
94 |
Less: treasury stock |
(3,435) |
(919) |
Total stockholders' equity |
52,516 |
48,213 |
|
|
|
Total liabilities and stockholders'
equity |
$ 63,184 |
$ 56,906 |
LEMAITRE VASCULAR,
INC (NASDAQ: LMAT) |
|
|
|
CONDENSED
CONSOLIDATED STATEMENT OF OPERATIONS |
|
|
|
(amounts in thousands, except
per share amounts) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the year
ended |
|
December 31,
2010 |
December 31,
2009 |
December 31,
2010 |
December 31,
2009 |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
Net sales |
$ 14,431 |
$ 13,584 |
$ 56,060 |
$ 50,908 |
Cost of sales |
4,084 |
3,411 |
14,341 |
13,604 |
|
|
|
|
|
Gross profit |
10,347 |
10,173 |
41,719 |
37,304 |
|
|
|
|
|
Operating expenses: |
|
|
|
|
Sales and marketing |
5,070 |
4,807 |
19,409 |
17,710 |
General and administrative |
2,864 |
2,421 |
10,506 |
9,852 |
Research and development |
1,475 |
1,716 |
5,488 |
5,910 |
Restructuring charges |
1,566 |
-- |
1,566 |
1,777 |
Impairment charge |
417 |
-- |
485 |
106 |
|
|
|
|
|
Total operating expenses |
11,392 |
8,944 |
37,454 |
35,355 |
|
|
|
|
|
Income (loss) from operations |
(1,045) |
1,229 |
4,265 |
1,949 |
|
|
|
|
|
Other income: |
|
|
|
|
Interest income, net |
6 |
8 |
26 |
12 |
Other income (expense), net |
(13) |
75 |
(16) |
254 |
|
|
|
|
|
Total other income, net |
(7) |
83 |
10 |
266 |
|
|
|
|
|
Income (loss) before income taxes |
(1,052) |
1,312 |
4,275 |
2,215 |
|
|
|
|
|
Provision (benefit) for income taxes |
(3,176) |
43 |
(1,898) |
617 |
|
|
|
|
|
Net income |
$ 2,124 |
$ 1,269 |
$ 6,173 |
$ 1,598 |
|
|
|
|
|
Net income per share of common stock: |
|
|
|
|
Basic |
$ 0.14 |
$ 0.08 |
$ 0.40 |
$ 0.10 |
Diluted |
$ 0.13 |
$ 0.08 |
$ 0.38 |
$ 0.10 |
|
|
|
|
|
Weighted average shares outstanding: |
|
|
|
|
Basic |
15,596 |
15,722 |
15,627 |
15,687 |
Diluted |
16,148 |
16,066 |
16,114 |
15,916 |
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
|
|
|
|
|
|
SELECTED NET SALES
INFORMATION |
|
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three
months ended |
For the year
ended |
|
December 31,
2010 |
December 31,
2009 |
December 31,
2010 |
December 31,
2009 |
|
$ |
% |
$ |
% |
$ |
% |
$ |
% |
|
(unaudited) |
|
|
(unaudited) |
|
|
Net Sales by Product
Category: |
|
|
|
|
|
|
|
|
Vascular |
$ 10,287 |
71% |
$ 9,364 |
69% |
$ 40,022 |
71% |
$ 34,265 |
67% |
Endovascular |
3,106 |
22% |
3,079 |
23% |
12,040 |
22% |
12,363 |
24% |
General Surgery |
975 |
7% |
1,007 |
7% |
3,882 |
7% |
3,836 |
8% |
|
14,368 |
100% |
13,450 |
99% |
55,944 |
100% |
50,464 |
99% |
OEM |
63 |
0% |
134 |
1% |
116 |
0% |
444 |
1% |
Total Net Sales |
$ 14,431 |
100% |
$ 13,584 |
100% |
$ 56,060 |
100% |
$ 50,908 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales by
Geography |
|
|
|
|
|
|
|
|
Americas |
$ 8,768 |
61% |
$ 7,704 |
57% |
$ 34,574 |
62% |
$ 29,420 |
58% |
International |
5,663 |
39% |
5,880 |
43% |
21,486 |
38% |
21,488 |
42% |
Total Net Sales |
$ 14,431 |
100% |
$ 13,584 |
100% |
$ 56,060 |
100% |
$ 50,908 |
100% |
LEMAITRE VASCULAR, INC
(NASDAQ: LMAT) |
|
|
|
|
|
|
|
|
|
|
|
IMPACT OF FOREIGN
CURRENCY AND BUSINESS ACTIVITIES |
|
|
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
2010 |
2009 |
2008 |
|
Q4 |
Q3 |
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
Q4 |
Q3 |
Q2 |
Q1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net sales |
14,431 |
13,656 |
14,158 |
13,815 |
13,584 |
13,346 |
12,630 |
11,348 |
12,111 |
12,023 |
12,739 |
11,847 |
Impact of currency exchange rate fluctuations
(1) |
(420) |
(418) |
(336) |
314 |
613 |
(215) |
(699) |
(622) |
(448) |
452 |
836 |
674 |
Net impact of acquisitions, distributed sales
and discontinued products, excluding currency exchange rate
fluctuations (2) |
56 |
(105) |
(65) |
95 |
397 |
333 |
234 |
101 |
235 |
703 |
929 |
1,133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Represents the impact of the
change in foreign exchange rates compared to the corresponding
quarter of the prior year based on the weighted averge exchange
rate for each quarter. |
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Represents the impact of
sales of products of acquired businesses and distributed sales of
other manufacturers' products, net of sales related to discontinued
products and other activities, based on 12 months' sales following
the date of the event or transaction, for the current period
only. |
LEMAITRE VASCULAR, INC (NASDAQ:
LMAT) |
|
|
|
NON-GAAP FINANCIAL
MEASURES |
|
|
|
(amounts in thousands) |
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP
sales growth: |
|
|
|
For the three months ending December 31,
2010 |
|
|
|
Net sales as reported |
$ 14,431 |
|
|
Impact of currency exchange
rate fluctuations |
420 |
|
|
Net impact of acquisitions, distributed
sales and discontinued products, excluding currency |
(56) |
|
|
Adjusted net sales |
|
$ 14,795 |
|
|
|
|
|
For the three months ending December 31,
2009 |
|
|
|
Net Sales as reported |
|
$ 13,584 |
|
|
|
|
|
Adjusted net sales increase for the
three months ending December 31, 2010 |
|
$ 1,211 |
9% |
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP
sales growth: |
|
|
|
For the year ending December 31,
2010 |
|
|
|
Net sales as reported |
$ 56,060 |
|
|
Impact of currency exchange
rate fluctuations |
860 |
|
|
Net impact of acquisitions, distributed
sales and discontinued products, excluding currency |
19 |
|
|
Adjusted net sales |
|
$ 56,939 |
|
|
|
|
|
For the year ending December 31,
2009 |
|
|
|
Net Sales as reported |
|
$ 50,908 |
|
|
|
|
|
Adjusted net sales increase for
the year ending December 31, 2010 |
|
$ 6,031 |
12% |
|
|
|
|
|
|
|
|
|
For the three
months ended |
|
|
December 31,
2010 |
December 31,
2009 |
|
Reconciliation between GAAP and Non-GAAP
income (loss) from operations: |
|
|
|
Income (loss) from operations as
reported |
$ (1,045) |
$ 1,229 |
|
Restructuring charges |
1,566 |
0 |
|
Impairment |
417 |
0 |
|
|
|
|
|
Adjusted income (loss) from
operations |
$ 938 |
$ 1,229 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CONTACT: J.J. Pellegrino
Chief Financial Officer
LeMaitre Vascular Inc.
781.221.2266 x106
jpellegrino@lemaitre.com
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From May 2024 to Jun 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Jun 2023 to Jun 2024